Literature DB >> 20491648

Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?

M Berg1, P Van der Veken, A Goeminne, A Haemers, K Augustyns.   

Abstract

For many years, the purine salvage pathway of parasitic protozoa has been regarded as an attractive chemotherapeutic target. Parasitic protozoa lack de novo synthesis and rely entirely on the purine salvage pathway to meet their purine demands. Because of the great phylogenetic difference between parasite and host, there are often sufficient distinctions that can be exploited to design specific inhibitors for the parasitic enzymes. As a result, this pathway has been thoroughly investigated over the last twenty years. It is only quite recently that the genome studies of Trypanosoma, Leishmania and Plasmodium have been published. Based on these genomic data however, the existence of by-pass mechanisms by other enzymes and transporter systems could be suggested. Taking into account such proposition, the question might arise as to whether inhibition of a single salvage enzyme will be able or not to cause parasite death or growth arrest. In this paper, the key enzymes in the purine salvage pathways of relevant pathogenic species from the genera Trypanosoma, Leishmania and Plasmodium are reviewed. Their potential as drug targets is critically evaluated and where possible, correlated to literature data on antiparasitic activity of their inhibitors. While many studies over the past ten years have yielded contradictory results, this review attempts to clarify these findings by discussing the latest elements of progress in the field. Additionally, as part of a broader discussion on substrate analogue types of inhibitors, special attention is paid to iminoribitol derivatives, serving as transition state analogues of nucleoside-processing enzymes and comprising the most potent inhibitors reported for purine salvage enzymes. More specifically, the development of three generations of immucillins and a newer series of N-(arylmethyl-) substituted iminoribitol derivatives will be discussed. Finally, this review also covers subversive substrates of salvage enzymes: compounds that are transformed by enzymatic activity into cytotoxic agents. Although not by directly intervening in the process of purine recovery, the subversive substrate approach might deliver antiprotozoal compounds that rely on salvage enzymes for their activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20491648     DOI: 10.2174/092986710791556023

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  28 in total

1.  Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

Authors:  Maya Berg; Raquel García-Hernández; Bart Cuypers; Manu Vanaerschot; José I Manzano; José A Poveda; José A Ferragut; Santiago Castanys; Jean-Claude Dujardin; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  GMP synthase is essential for viability and infectivity of Trypanosoma brucei despite a redundant purine salvage pathway.

Authors:  Qiong Li; Christopher Leija; Filipa Rijo-Ferreira; Jun Chen; Igor Cestari; Kenneth Stuart; Benjamin P Tu; Margaret A Phillips
Journal:  Mol Microbiol       Date:  2015-07-04       Impact factor: 3.501

Review 3.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

Review 4.  Dependence of Leishmania parasite on host derived ATP: an overview of extracellular nucleotide metabolism in parasite.

Authors:  Kashika Arora; Ambak Kumar Rai
Journal:  J Parasit Dis       Date:  2018-12-01

5.  Structural explanation for the tunable substrate specificity of an E. coli nucleoside hydrolase: insights from molecular dynamics simulations.

Authors:  Stefan A P Lenz; Stacey D Wetmore
Journal:  J Comput Aided Mol Des       Date:  2018-11-26       Impact factor: 3.686

Review 6.  Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria.

Authors:  Rodrigo G Ducati; Hilda A Namanja-Magliano; Vern L Schramm
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

Review 7.  Immucillins in Infectious Diseases.

Authors:  Gary B Evans; Peter C Tyler; Vern L Schramm
Journal:  ACS Infect Dis       Date:  2017-12-05       Impact factor: 5.084

8.  Divergent metabolism between Trypanosoma congolense and Trypanosoma brucei results in differential sensitivity to metabolic inhibition.

Authors:  Pieter C Steketee; Emily A Dickie; James Iremonger; Kathryn Crouch; Edith Paxton; Siddharth Jayaraman; Omar A Alfituri; Georgina Awuah-Mensah; Ryan Ritchie; Achim Schnaufer; Tim Rowan; Harry P de Koning; Catarina Gadelha; Bill Wickstead; Michael P Barrett; Liam J Morrison
Journal:  PLoS Pathog       Date:  2021-07-26       Impact factor: 6.823

Review 9.  Nano-Medicines a Hope for Chagas Disease!

Authors:  Satabdi Datta Choudhury
Journal:  Front Mol Biosci       Date:  2021-06-01

10.  Pyrimidine biosynthesis is not an essential function for Trypanosoma brucei bloodstream forms.

Authors:  Juma A M Ali; Daniel N A Tagoe; Jane C Munday; Anne Donachie; Liam J Morrison; Harry P de Koning
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.